Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
|Podcasts|August 19, 2022
Pharmacy Focus Episode 53: Expanding Diversity, Equity in Clinical Health Trials
Using specific data and technology can help advance targeted recruitment goals for trials.
Advertisement
In this week’s episode, we will be discussing clinical trial updates and incorporating equity and diversity in trials with Tony Clapsis, Senior Vice President and head of CVS Health Clinical Trial Services. If you would like to nominate a pharmacist or pharmacy staff member as a Pharmacy Hero, email [email protected]!
Advertisement
Related to this article
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, whereas sulfonylureas signaled faster decline without it.
Authors of a pharmacist-directed transitions-of-care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
FDA Approves Belzutifan Plus Lenvatinib for Advanced Renal Cell Carcinoma After Immunotherapy
4
Harnessing the Gut Microbiome for Enhanced CAR T Cell Therapy
5